Estija - estų - Ravimiamet

actavis group ptc ehf. - ambroksool - suukaudne lahus - 6mg 1ml 100ml 1tk; 6mg 1ml 200ml 1tk

Estija - estų - Ravimiamet

actavis group ptc ehf. - desogestreel - õhukese polümeerikattega tablett - 75mcg 168tk; 75mcg 84tk

Estija - estų - Ravimiamet

actavis group ptc ehf. - ambroksool - suukaudne lahus - 3mg 1ml 200ml 1tk; 3mg 1ml 100ml 1tk

Estija - estų - Ravimiamet

actavis group ptc ehf. - ampitsilliin+sulbaktaam - süste-/infusioonilahuse pulber - 2000mg+1000mg 10tk

Estija - estų - Ravimiamet

actavis group ptc ehf. - diklofenak - geel - 10mg 1g 60g 1tk

Estija - estų - Ravimiamet

actavis group ptc ehf. - tseftasidiim - infusioonilahuse pulber - 2000mg 5tk; 2000mg 10tk; 2000mg 1tk

Europos Sąjunga - estų - EMA (European Medicines Agency)

actavis group ptc ehf - imatiniib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. mõju imatinib tulemuste kohta luuüdi siirdamine ei ole kindlaks. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. kogemus imatinib patsientidel mds/mpd seotud pdgfr geeni taas-kord on väga piiratud. puuduvad kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Estija - estų - Ravimiamet

actavis group ptc ehf. - olansapiin - õhukese polümeerikattega tablett - 15mg 14tk; 15mg 28tk; 15mg 500tk; 15mg 56tk; 15mg 30tk; 15mg 7tk; 15mg 70tk; 15mg 35tk; 15mg 100tk

Estija - estų - Ravimiamet

actavis group ptc ehf. - klopidogreel - õhukese polümeerikattega tablett - 75mg 90tk; 75mg 30tk; 75mg 60tk; 75mg 20tk; 75mg 56tk; 75mg 7tk; 75mg 100tk; 75mg 28tk; 75mg 50tk; 75mg 14tk; 75mg 10tk

Estija - estų - Ravimiamet

actavis group ptc ehf. - olansapiin - õhukese polümeerikattega tablett - 20mg 28tk; 20mg 7tk; 20mg 30tk; 20mg 100tk; 20mg 35tk; 20mg 56tk; 20mg 500tk